Protocol Ledger

NCT07665450 · Phase III · RECRUITING

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant

Interventional Phase III clinical trial protocol NCT07665450 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-09 Enrollment: 1,000 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07665450
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,000 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07665450
Protocol FieldVerified Registry Value
NCT IdentifierNCT07665450
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,000 participants (ESTIMATED)
Registered Start Date2026-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07665450
Hospital Research SiteLocationSite Profile
Fakultni nemocnice BrnoBrno, CzechiaOpen Hospital Dossier ->
Fakultni nemocnice Hradec KraloveHradec Králové, CzechiaOpen Hospital Dossier ->
Fakultni nemocnice Kralovske VinohradyPrague, CzechiaOpen Hospital Dossier ->
Vseobecna fakultni nemocnice v PrazePrague, CzechiaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI